Fig. 3.

Therapy targets for prevention of atherothrombosis. Reduction of LDL (and other large lipoproteins) by lipid-lowering therapy and prevention of LDL retention in the artery wall, both act to reduce cholesterol accumulation, an initiator of atherosclerosis. Stimulation of immunoregulatory mechanisms reduces vascular inflammation; they include administration of anti-inflammatory cytokines, enhancing Treg cells and vaccination to elicit atheroprotective immunity. Mediators of resolution include resolvin-type eicosanoids, peptide mimetics of Annexin I and other substances.